¿Cómo es el uso de medicamentos opioides en España? Análisis de los datos de la encuesta EDADES 2017

  1. Esperanza Regueras 1
  2. José López Guzmán 1
  1. 1 Universidad de Navarra
    info

    Universidad de Navarra

    Pamplona, España

    ROR https://ror.org/02rxc7m23

Revista:
MPJ Multidisciplinary Pain Journal

ISSN: 2697-2263

Any de publicació: 2021

Número: 1

Tipus: Article

DIALNET GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: MPJ Multidisciplinary Pain Journal

Resum

Objectives: Quantify the level of use of opioid medicines in this general population, the level of follow-up to prescribed guidelines, the reason for use, and the means of obtaining these medicines in Spain. Methodology: Analysis of the raw data for the EDADES 2017 study that has been conducted in Spain every two years since 1995 among the general population (15 to 64 years of age). After categorizing and cleaning the data, several pivot tables were performed to extract the desired information. Results: In Spain the prevalence of any opioid drug use at 12 months was 6.7 % of the population between 15 and 64 years of age. 87 % of this use was associated with weak opioids (tramadol or codeine) and the rest was related to major opioids, with morphine being the most widely used with 8% of total opioid users. 92 % of people obtained the medicine through their own prescription while 4 % obtained it at the pharmacy without a prescription and an additional 3 % obtained it through friends or family. 74 % of patients had followed the dose and duration of treatment guidelines prescribed by the doctor, while 19 % had used opioid medicines in lower doses or for less time than prescribed. Conclusions: Use of strong opioids is low in Spain, most patients use it under medical supervision and following the guidelines prescribed by the doctor. Patients who obtain opioid medications without their own prescription as well as those who use it differently than the prescribed one need to be tracked.

Referències bibliogràfiques

  • Roehr B. Trump declares opioid public health emergency but no extra money. BMJ. 2017;359:j4998. DOI: 10.1136/bmj.j4998.
  • McCarthy M. US declares opioid epidemic a “national emergency”. BMJ. 2017;358:j3881. DOI: 10.1136/bmj.j3881.
  • Bonnie RJ, Kesselheim A, Clark DJ. Both Urgency and Balance Needed in Addresing Opioid Epidemic: A Report From the National Academies of Sciences, Engineering and Medicine. JAMA. 2017;318(5):423-4. DOI: 10.1001/jama.2017.10046.
  • Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ. The Economic Burden of Opioid Abuse: Updated Findings. J Manag Care Spec Pharma. 2017;23(4):427-45. DOI: 10.18553/jmcp.2017.16265.
  • Pollack H. Prescription Opioid Disorders are a 785$ billon problem. Med Care. 2016;54(1):899-900. DOI: 10.1097/MLR.0000000000000652.
  • Delegación del Gobierno para el Plan Nacional Sobre Drogas [Internet]. Ministerio de Sanidad; 2021 [citado el 31 de enero de 2021]. Disponible en: https://pnsd.sanidad.gob.es/profesionales/sistemasInformacion/home.htm
  • Delegación del Gobierno para el Plan Nacional sobre Drogas. EDADES 2017. Encuesta sobre alcohol y otras drogas en España [Internet]. 2017 [citado el 31 de enero de 2021]. Disponible en: https://pnsd.sanidad.gob.es/profesionales/sistemasInformacion/sistemaInformacion/pdf/EDADES_2017_Informe.pdf
  • Herrera-Gómez F, Gutierrez-Abejón E, Ayestarán I, Criado-Espegel P, FJ Álvarez. The Trends in Opioid Use in Castile and Leon, Spain: A Population-Based Registry Analysis of Dispensations in 2015 to 2018. J Clin Med. 2019;8(12):2148. DOI: 10.3390/jcm8122148.
  • AEMPS Agencia Española de Medicamentos y Productos Sanitarios. Agencia Española de Medicamentos y Productos Sanitarios AEMPS [Internet]. Fentanilo de liberación inmediata: importancia de respetar las condiciones de uso autorizadas. 1-4. 2018 [citado en mayo de 2019]. Disponible en: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2018/docs/NI_MUH_FV-5_2018-Fentanilo.pdf
  • SAMHSA (Substance abuse and Mental Health Services Administration. 2017. National Survey on Drug Use and Health [Internet]. U. S. Department of Health and Human Services [citado el 22 de abril de 2020]. Disponible en: https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report
  • SAMHSA (Substance abuse and Mental Health Services Administration. 2018. National Survey on Drug Use and Health [Internet]. U. S. Department of Health and Human Services [citado el 22 de abril de 2020]. Disponible en: https://www.samhsa.gov/data/release/2018-national-survey-drug-use-and-health-nsduh-releases
  • 114th Congress. 21st Century Cures Act. Public Law 114-255. DEC. 13, 2016 130 STAT. 1033.
  • O’Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ. Position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21:3-19. DOI: 10.1002/ejp.970.
  • Delegación de Gobierno de España para el Plan Nacional sobre Drogas. EDADES 2019/2020. Encuesta sobre alcohol, droga y otras adicciones en España [Internet]. Gobierno de España; 2019 [citado el 31 de enero de 2021]. Disponible en: https://pnsd.sanidad.gob.es/profesionales/sistemasInformacion/sistemaInformacion/pdf/EDADES_2019-2020_resumenweb.pdf
  • Clark J, Nijs J, Yeowell G, Goodwin PC. What are the predictors of altered Central pain modulation in chronic musculoskeletal pain populations? A systematic review. Pain Physician. 2017;20(6):487-500. DOI: 10.36076/ppj.2017.20.5.487.
  • Pozek JP, Beausang D, Baratta JL, Viscusi ER. The acute to chronic pain transition: can chronic pain be prevented? Med Clin North Am. 2016;100(1):17-30. DOI: 10.1016/j.mcna.2015.08.005.
  • Rockville M. Substance Abuse and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Mental Health Findings, NSDUH Series H-45, HHS. SAMHSA.
  • Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901-6. DOI: 10.1097/MLR.0000000000000625.
  • Scarpati LM, Kirson NY, Zichlin ML, Jia ZB, Birnbaum HG, Howard JC. Drivers of excess costs of opioid abuse among a commercially insured population. Am J Manag Care. 2017;23(5):276-82.
  • Kochanek KD. Mortality in the United States. Bost Med Surg J. 2017;(3):46-7.
  • Frenk SM, Lukacs SL, Gu Q. Factors Associated with prescription opoid analgesic use in the US population, 2011-2014. Pain Med. 2019;20(7):1338-46. DOI: 10.1093/pm/pny158.
Fuente de los datos: Dialnet